{
  "hfpef": {
    "acc_aha_2022": {
      "disease": "HFpEF",
      "last_updated": "2022-04-01",
      "recommendations": [
        {
          "therapy_class": "SGLT2 Inhibitor",
          "recommendation_class": "Class I",
          "level_of_evidence": "A",
          "description": "SGLT2 inhibitors are recommended to reduce heart failure hospitalizations and cardiovascular mortality in patients with HFpEF."
        },
        {
          "therapy_class": "ARNI",
          "recommendation_class": "Class IIa",
          "level_of_evidence": "B-R",
          "description": "ARNI may be beneficial to reduce heart failure hospitalizations in selected patients with HFpEF."
        },
        {
          "therapy_class": "ACEi/ARB",
          "recommendation_class": "Class IIb",
          "level_of_evidence": "C-LD",
          "description": "ACE inhibitors or ARBs may be considered to reduce hospitalizations in patients with HFpEF."
        }
      ]
    },
    "esc_2021": {
      "disease": "HFpEF",
      "last_updated": "2021-08-27",
      "recommendations": [
        {
          "therapy_class": "SGLT2 Inhibitor",
          "recommendation_class": "Class I",
          "level_of_evidence": "A",
          "description": "SGLT2 inhibitors are recommended in patients with HFpEF to reduce the risk of HF hospitalizations and cardiovascular death."
        },
        {
          "therapy_class": "ARNI",
          "recommendation_class": "Class IIa",
          "level_of_evidence": "B",
          "description": "ARNI should be considered to reduce the risk of HF hospitalizations in patients with HFpEF."
        }
      ]
    }
  }
}

